Y. Azuma et al., Cholesterol-lowering effects of NTE-122, a novel acyl-CoA : cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits, JPN J PHARM, 78(3), 1998, pp. 355-364
Pharmacological characterization of NTE-122 (trans-1,4-bis[[1-cyclohexyl-3-
(4-dimethyl-amino phenyl)ureido]methyl] cyclohexane), a novel acyl-CoA: cho
lesterol acyltransferase (ACAT) inhibitor, was performed with both in vitro
and in vivo assay systems. NTE-122 inhibited microsomal ACAT activities of
various tissues (liver of rabbit and rat, small intestine of rabbit and ra
t, and aorta of rabbit) and cultured cells (HepG2 and CaCo-2), with IC50 va
lues from 1.2 to 9.6 nM. The inhibition mode of NTE-122 was competitive for
HepG2 ACAT. NTE-122 had no effect on other lipid metabolizing enzymes, suc
h as 3-hydroxy-3-methylglutaryl-CoA reductase, acyl-CoA synthetase, cholest
erol esterase, lecithin:cholesterol acyltransferase, acyl-CoA:sn-glycerol-3
-phosphate acyltransferase and cholesterol 7 alpha-hydroxylase up to 10 mu
M. When NTE-122 was administered to the cholesterol diet-fed rats, serum an
d liver cholesterol levels were markedly reduced with an ED50 Of 0.12 and 0
.44 mg/kg/day, respectively. In the cholesterol diet-fed rabbits, NTE-122 s
ignificantly lowered plasma and liver cholesterol levels at more than 2 mg/
kg/day. These results indicate that NTE-122 is a potent, selective and comp
etitive inhibitor of ACAT, making it a worth while therapeutic agent for hy
percholesterolemia and atherosclerosis.